Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma

NCT00992173 is registered in ClinicalTrials.gov with Molecular Insight Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00992173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2010
Completion date
Not reported
Enrollment
0 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma